Status:
COMPLETED
Direct Injection of Alcohol for the Treatment of Spinal Tumors
Lead Sponsor:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Hemangioma
Neoplasm Metastasis
Eligibility:
All Genders
Brief Summary
Tumors of the spine can be described as primary, meaning that the tumor originated from cells normally found in the spine, or metastatic, cells from another area of the body that have spread to the sp...
Detailed Description
Although radiation therapy is currently the treatment of choice for most spinal metastases, radioresistant and recurrent neoplasms remain therapeutic dilemmas. Because of the debility and shortened li...
Eligibility Criteria
Patients must have a vertebral tumor documented by MRI.
Vertebral height must be at least 50 percent of adjacent vertebrae.
Patients must be symptomatic from their spinal tumor. Treatment attempts to reduce the size of, or eliminate, their tumors and to relieve their symptoms. The treatment of the vertebral tumor must be indicated based on the patient's condition.
Prior surgical or radiation therapy for the vertebral tumor will not result in exclusion from the study if there is radiographic evidence of tumor and there is evidence of persistent local pain, epidural compression, or neurological deterioration related to the vertebral tumor.
The patient must be able to comprehend the risks of the therapy and must be able to give informed consent.
Pregnancy will exclude participation due to the radiation exposure involved in this protocol.
Bleeding disorders will exclude a patient from the protocol unless the disorder can be corrected prior to treatment.
Patients must have no contraindications to MRI scanning.
Patients undergoing ethanol injection in the x-ray department must be able to lay prone for at least one hour with intravenous sedation and analgesia.
Patients whose tumors have not responded to radiation therapy will be candidates for ethanol infusion.
Patients with tumors in areas that have received maximal radiation doses to the spinal cord will be candidates for ethanol infusion.
Patients whose poor general condition precludes open surgery will be candidates for ethanol infusion.
Patients who wish to avoid the morbidity and potential mortality of open surgery will be candidates for ethanol injection.
Patients with radioresistant tumors such as melanoma or prostate carcinoma are candidates for ethanol infusion even if they have not undergone prior irradiation.
Patients with radiation-sensitive spinal tumors such as breast, kidney, and lung carcinoma, lymphoma, myeloma, Ewing's sarcoma, neuroblastoma, seminoma will not be entered into the protocol unless their tumors have either responded to radiation or lie at spinal cord levels that have already received maximal tolerable radiation doses.
Patients with less than a 2 month life expectancy will be excluded.
Patients with symptomatic vertebral metastases at more than 3 spinal levels will be excluded.
Patients with asymptomatic vertebral metastases will be excluded.
Key Trial Info
Start Date :
June 1 1994
Trial Type :
OBSERVATIONAL
End Date :
May 1 2002
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00001417
Start Date
June 1 1994
End Date
May 1 2002
Last Update
March 4 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, United States, 20892